Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Clarus Therapeutics Inc.

Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Pediatric Testosterone Therapy: Sponsors Wary Of Trials Despite PREA

Studies are unfeasible, sponsors argue in advance of US advisory committee meeting that could lead to FDA ending its waiver on requiring clinical trials in pediatric patients for new testosterone replacement therapy products.

Advisory Committees Clinical Trials

Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS

Jatenzo clears US FDA 15 months after second negative advisory committee review. 

Approvals Drug Safety
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register